Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony S Mok

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Human Pathology|August 22, 2008
Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patientsRong Li, She-Juan An, Zhi-Hong Chen, et al.
European Journal of Pharmacology|June 29, 2007
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with GefitinibQiang Nie, Zhen Wang, Guo-Chun Zhang, et al.
Cancer Letters|April 15, 2008
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsJian-quan Zhu, Wen-zhao Zhong, Guo-chun Zhang, et al.
Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for <i>EGFR</i> mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung CancerChao Li, Cheng Huang, Tony S Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung CancerBenjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Clinical Lung Cancer|April 15, 2018
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of ImmunotherapyNavika D Shukla, Ameen A Salahudeen, Gregory A Taylor, et al.
Theranostics|January 2, 2018
Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomasLili Li, Juan Xu, Guohua Qiu, et al.
Theranostics|February 24, 2022
Erratum: Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: ErratumLili Li, Juan Xu, Guohua Qiu, et al.
Future Oncology (London, England)|November 9, 2020
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050Jean Paty, Rickard Sandin, Arlene Reisman, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Human Pathology|August 22, 2008
Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patientsRong Li, She-Juan An, Zhi-Hong Chen, et al.
European Journal of Pharmacology|June 29, 2007
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with GefitinibQiang Nie, Zhen Wang, Guo-Chun Zhang, et al.
Cancer Letters|April 15, 2008
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsJian-quan Zhu, Wen-zhao Zhong, Guo-chun Zhang, et al.
Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for <i>EGFR</i> mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung CancerChao Li, Cheng Huang, Tony S Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung CancerBenjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Clinical Lung Cancer|April 15, 2018
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of ImmunotherapyNavika D Shukla, Ameen A Salahudeen, Gregory A Taylor, et al.
Theranostics|January 2, 2018
Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomasLili Li, Juan Xu, Guohua Qiu, et al.
Theranostics|February 24, 2022
Erratum: Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: ErratumLili Li, Juan Xu, Guohua Qiu, et al.
Future Oncology (London, England)|November 9, 2020
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050Jean Paty, Rickard Sandin, Arlene Reisman, et al.
Pageof 5